With narcolepsy trial win, Axsome looks to revive former Pfizer antidepressant on the US market

Once a controversial European depression treatment that never made it to the U.S. market, reboxetine may soon see new life under Axsome Therapeutics' stewardship.

Since collecting the exclusive U.S. rights and data on the drug from Pfizer in 2020, Asxome has been busy building on its two earlier studies of AXS-12 in narcolepsy. Now, with fresh phase 3 data in hand, the company plans to head to the FDA to see if the drug can make a comeback.